Bioventus Inc. (BVS) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-14

Key Insights

Insider Anthony D'Adamio, the SVP & General Counsel, exercised 9,925 restricted stock units and disposed of 4,312 shares of Class A common stock, suggesting potential wealth diversification.
The transaction price of $9.06 per share suggests the stock is trading at a reasonable valuation compared to the exercise price of $0 for the restricted stock units.
The remaining 153,655 shares of Class A common stock held by Anthony D'Adamio indicate his continued alignment with Bioventus Inc.'s long-term success.

Want the newest filings?

This analysis covers the filing from 2026-04-14. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-14

Katrina J. Church, SVP & Chief Compliance Officer, exercised 4,300 restricted stock units and sold 1,868 shares of Class A common stock, reducing her direct ownership to 64,164 shares.
The transaction was executed on April 10, 2026, with the shares being sold at a price of $9.06 per share.
This insider transaction suggests that the executive is monetizing a portion of her equity holdings, which could indicate her confidence in the company's near-term performance or a personal financial need.

Filed: 2026-04-14

Mark Leonard Singleton, the SVP & CFO of Bioventus Inc. (BVS), has exercised 13,000 restricted stock units (RSUs) and disposed of 5,648 shares of Class A common stock through a 'net settlement' transaction.
The exercised RSUs and the subsequent share disposition indicate that the reporting person is monetizing a portion of his equity-based compensation, which could signal his confidence in the company's financial performance.
The reported transaction represents a relatively small portion of the reporting person's total beneficial ownership, which remains at 177,333 shares of Class A common stock following the reported transactions.

Filed: 2026-03-24

The reporting person, Mark Leonard Singleton, is the SVP & CFO of Bioventus Inc., indicating this is an important insider transaction.
Singleton exercised 18,625 restricted stock units (RSUs) and sold 8,091 shares, potentially to cover taxes, suggesting he continues to hold a significant equity stake in the company.
The timing and size of this transaction suggest the reporting person remains confident in Bioventus' long-term prospects, as he is not significantly reducing his ownership position.

Filed: 2026-03-17

The reporting person, Robert E. Claypoole, acquired 134,000 restricted stock units and 153,000 stock options, indicating potential confidence in the company's future performance.
Claypoole also disposed of 14,553 shares of Class A common stock, likely for tax or liquidity purposes, but maintains a sizable ownership stake of 135,944 shares.
The vesting schedule of the restricted stock units and stock options suggests a long-term incentive alignment between Claypoole and Bioventus Inc. shareholders.

Filed: 2026-03-17

The reporting person, Anthony D'Adamio, who is the SVP and General Counsel of Bioventus Inc. (BVS), made multiple transactions involving the company's Class A common stock and derivative securities.
D'Adamio exercised 8,886 restricted stock units (RSUs) and 8,750 RSUs, and then sold 3,861 and 3,802 shares to cover tax withholding, indicating continued ownership and vesting of equity awards.
The reporting person also received new grants of 35,000 RSUs and 40,000 stock options, as well as an additional 83,000 RSUs and 92,000 stock options, vesting over the next four years, signaling long-term incentive alignment with shareholders.

Filed: 2026-03-17

Insider Katrina J. Church, SVP & Chief Compliance Officer, exercised 6,955 stock options and restricted stock units, indicating ongoing commitment to the company.
Church sold 3,022 shares to cover tax withholding obligations, suggesting she is not cashing out a significant portion of her holdings.
The reported transactions align with Church's previous equity awards, suggesting a routine exercise of vested equity rather than a material change in her ownership position.

Filed: 2026-03-17

Insider Mark Leonard Singleton, SVP & CFO of Bioventus Inc. (BVS), exercised 13,500 stock options and sold 5,865 shares, indicating he is reducing his direct ownership in the company.
Singleton received 54,000 new restricted stock units (RSUs) and 61,000 stock options, which will vest in four equal installments over the next four years, aligning his interests with the company's long-term performance.
The company appears to be providing Singleton with a significant equity-based compensation package, which could be a sign of the board's confidence in his leadership and the company's future prospects.

Filed: 2026-01-13

Insider Robert E. Claypoole, who is the President and CEO, acquired 93,750 shares of Bioventus Inc. (BVS) through the vesting of restricted stock units (RSUs) on January 9, 2026.
Claypoole then sold 41,717 shares to cover tax withholding obligations, leaving him with a net increase of 52,033 shares in his direct ownership.
The reported transactions suggest that Claypoole remains confident in the company's outlook and is aligning his interests with shareholders by maintaining a substantial direct ownership stake.

Other reports for Bioventus Inc.

Current Report Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.